Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...
In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.
Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...
Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback